Amgen Ventures Invests in GNS Healthcare to Advance Applications of its REFS™ Causal Machine Learning and Simulation AI Platforms

CAMBRIDGE, Mass.– August 23, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced that it has raised an additional $6 million in equity from Amgen Ventures with participation from existing investor Alexandria Real Estate Equities. The funds will be used to further develop the company’s REFS™ causal machine learning and simulation platform and solutions […]

FierceBiotech features Alexion-GNS Partnership Targeting Rare Diseases

Alexion inks genomics pacts to continue R&D reboot August 11, 2017  – Alexion has teamed up with GNS Healthcare and Sema4 to advance its rare disease R&D agenda. The partnerships give Alexion access to modeling and simulation software used by Celgene and a partner to support its push into genomics. Read the full article here. […]

Rare Disease Report Covers Alexion-GNS REFS Licensing Agreement

Rare Disease Treatments to Be Discovered by Machine Learning and Simulation Platform August 10, 2017 – Earlier today, Alexion Pharmaceuticals was granted the licensing rights to operate GNS Healthcare’s Reverse Engineering and Forward Simulation (REFS) casual machine learning and simulation platform. Alexion intends to use the platform to accelerate both the research of rare diseases […]

GNS Co-Founder Iya Khalil Interviewed in The Pink Sheet

At the 2017 BIO International Convention, GNS Co-Founder and Chief Commercial Officer Iya Khalil sat down with Laura Helbling, the Director of Research at Prevision Policy and a Senior Writer at Pink Sheet to discuss machine learning in drug development. The conversation focused on how GNS’ causal machine learning and simulation platform applied to massive […]

GNS Healthcare Licenses REFS™ Causal Machine Learning and Simulation Platform to Alexion to Accelerate Discovery of New Treatments for Rare Diseases

CAMBRIDGE, Mass. – August 10, 2017– GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to large and diverse data sets to better match drugs and other health interventions to individual patients, today announced that it has entered into a license arrangement with Alexion for the rights to operate its REFS™ […]

Sema4 and GNS Healthcare Announce Collaboration Using REFS™ Causal Machine Learning and Simulation AI Platform

Working Towards New Therapies for Cardiovascular Disease Stamford, Conn. and Cambridge, Mass. – June 27, 2017– Sema4, an interdisciplinary health information company with expertise in collecting diverse data, building computational models of disease and unlocking solutions to disease, today announced it is leveraging GNS Healthcare’s (GNS), REFS™ (Reverse Engineering and Forward Simulation) causal machine learning […]

GNS Healthcare Uncovers Novel Targets for Triple-Negative Breast Cancer Using Causal Machine Learning and Simulation Platform REFS™

New Gene Discoveries Published by the American Association for Cancer Research CAMBRIDGE, Mass. – May 31, 2017– Leading precision medicine company GNS Healthcare (GNS), today announced the discovery of novel targets, including TRIB1, which correlates with survival, progression, and metastasis in resistant breast cancer. The study, which was conducted at University of California, San Francisco, […]

GNS Healthcare and Regence Blue Cross Blue Shield Co-Present Machine Learning Enhanced Advanced Illness Program at Annual Blues National Summit

CAMBRIDGE, Mass. – May 9, 2017– GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to large and diverse data sets to better match health interventions to individual patients to improve health outcomes and lower the total cost of care, will present its Advanced Illness solution, in collaboration with Regence Blue […]

GNS Taps Nationally Regarded Epidemiologist to Put Discoveries From Causal Machine Learning and Simulation Platform in ‘Clinical Context’

Veteran Healthcare Leader Julie Slezak Appointed to Executive Vice President of Clinical Analytics CAMBRIDGE, Mass. – April 4, 2017 – Leading precision medicine company GNS Healthcare (GNS) today announced that nationally regarded epidemiologist and biostatistician Julie Slezak has been named to the newly created position Executive Vice President of Clinical Analytics. Slezak, who previously headed […]

GNS Prominently Featured in BioCentury Cover Story on Use of Machine Learning by Pharma

Applying machine learning tools to drug R&D could usher in a new era of effective therapies targeting causative disease drivers, higher success rates in clinical trials and real world tools to manage adherence, prevent adverse events and reduce total healthcare costs. Download the complete article here.